

Acute Pyelonephritis in Adults: Rapid Evidence Review

Joel Herness, MD, Mike O'Callaghan Military Medical Center Family Medicine Residency Program, Nellis Air Force Base, Nevada

Amelia Buttolph, MD, Camp Lejeune Family Medicine Residency Program, Camp Lejeune, North Carolina

Noa C. Hammer, MD, MPH, Naval Hospital Camp Pendleton Family Medicine Residency Program, Camp Pendleton, California

Acute pyelonephritis is a bacterial infection of the kidney and renal pelvis and should be suspected in patients with flank pain and laboratory evidence of urinary tract infection. Urine culture with antimicrobial susceptibility testing should be performed in all patients and used to direct therapy. Imaging, blood cultures, and measurement of serum inflammatory markers should not be performed in uncomplicated cases. Outpatient management is appropriate in patients who have uncomplicated disease and can tolerate oral therapy. Extended emergency department or observation unit stays are an appropriate option for patients who initially warrant intravenous therapy. Fluoroquinolones and trimethoprim/sulfamethoxazole are effective oral antibiotics in most cases, but increasing resistance makes empiric use problematic. When local resistance to a chosen oral antibiotic likely exceeds 10%, one dose of a long-acting broad-spectrum parenteral antibiotic should also be given while awaiting susceptibility data. Patients admitted to the hospital should receive parenteral antibiotic therapy, and those with sepsis or risk of infection with a multidrug-resistant organism should receive antibiotics with activity against extended-spectrum beta-lactamase-producing organisms. Most patients respond to appropriate management within 48 to 72 hours, and those who do not should be evaluated with imaging and repeat cultures while alternative diagnoses are considered. In cases of concurrent urinary tract obstruction, referral for urgent decompression should be pursued. Pregnant patients with pyelonephritis are at significantly elevated risk of severe complications and should be admitted and treated initially with parenteral therapy. (*Am Fam Physician*. 2020;102(3):173-180. Copyright © 2020 American Academy of Family Physicians.)

Acute pyelonephritis, a serious and relatively common bacterial infection of the kidney and renal pelvis, accounts for approximately 250,000 office visits and 200,000 hospital admissions annually in the United States.¹⁻³

Epidemiology and Microbiology

- The highest incidence is among otherwise healthy women 15 to 29 years of age.³
- *Escherichia coli* accounts for approximately 90% of uncomplicated pyelonephritis cases^{4,5}; factors that define complicated pyelonephritis are listed in *Table 1*.^{6,7}
- Other causative organisms are more prevalent in complicated cases, but *E. coli* remains predominant^{4,5} (*eTable A*).

- As of 2014, *E. coli* resistance to trimethoprim/sulfamethoxazole and fluoroquinolones in the United States exceeded 35% and 10%, respectively.⁵
- Extended-spectrum beta-lactamase-producing uropathogenic organisms demonstrate resistance to third- and

WHAT'S NEW ON THIS TOPIC

Pyelonephritis

As of 2014, *Escherichia coli* resistance to trimethoprim/sulfamethoxazole and fluoroquinolones in the United States exceeded 35% and 10%, respectively.

A systematic review of 8 randomized controlled trials (N = 2,515) demonstrated equivalent clinical success rates in treating uncomplicated acute pyelonephritis with a 5- to 7-day course of fluoroquinolones compared with a 14-day course.

In the male subgroup of a 2017 randomized controlled trial, a 7-day course of ciprofloxacin was inferior to a 14-day course with respect to short-term cure rates, with no differences in long-term outcomes.

Additional content at <https://www.aafp.org/afp/2020/0801/p173.html>.

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 143.

Author disclosure: No relevant financial affiliations.

Patient information: A handout on this topic is available at <https://familydoctor.org/condition/kidney-infection/>.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Urine culture and antimicrobial susceptibility testing should be performed in patients with suspected acute pyelonephritis and used to direct antibiotic therapy. ⁷	C	Expert consensus guideline in the absence of clinical trials
Initial imaging should not be performed in uncomplicated cases of acute pyelonephritis. Contrast-enhanced computed tomography of the abdomen and pelvis is indicated in septic patients, when urinary obstruction is suspected, or when patients do not respond to appropriate therapy within 48 to 72 hours. ²³	C	Expert consensus guideline based on low-quality observational evidence
Fluoroquinolones (e.g., ciprofloxacin for 7 days or levofloxacin [Levaquin] for 5 days) and trimethoprim/sulfamethoxazole for 14 days are appropriate first-line oral antibiotic therapies for uncomplicated acute pyelonephritis in women when the causative organism is susceptible. ^{7,30}	A	Expert consensus based on consistent evidence from randomized controlled trials demonstrating effectiveness
In locations where <i>Escherichia coli</i> resistance to empiric oral therapy is likely greater than 10%, an initial broad-spectrum, long-acting parenteral antibiotic such as ceftriaxone, ertapenem (Invanz), or an aminoglycoside should be given concurrently. ⁷	B	Expert consensus based on lower quality clinical trials demonstrating benefit when combined with beta-lactams
Patients at increased risk of infection with multidrug-resistant organisms and those with sepsis should be treated with parenteral antibiotics that have activity against extended-spectrum beta-lactamase-producing organisms until susceptibility data are available. ⁷	C	Expert consensus guideline in the absence of clinical trials

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

fourth-generation cephalosporins and are increasingly prevalent in the United States and globally.⁵

- Risk factors for infection with multidrug-resistant organisms are listed in *Table 2*.^{5,7}

Diagnosis

- Flank pain and tenderness in the presence of pyuria are highly suggestive of pyelonephritis and differentiate it from other urinary tract infections.^{4,6,8,9}
- Fever is typically present but is not a universal symptom. Lower urinary tract symptoms (e.g., frequency, urgency, dysuria) may be absent in as many as 20% of patients.^{4,6,8,9}
- Other potential signs and symptoms of pyelonephritis include the following^{4,6,8,9}:
 - Constitutional symptoms (e.g., fever, chills, malaise)
 - Nausea, vomiting, and abdominal pain
 - Abdominal or suprapubic tenderness
 - Tachycardia or hypotension

DIAGNOSTIC TESTING

- Urine culture with antimicrobial susceptibility testing should be performed in all patients; when clinically reasonable, urine culture should be performed before the patient receives antibiotics.⁷
- Several studies demonstrate no reduction in contamination rates with preparatory cleansing or midstream catch; catheterization is not necessary for specimen collection.¹⁰⁻¹³

- A basic metabolic profile and complete blood count help evaluate severity and can identify complications, particularly renal failure.^{9,14}
- Serum inflammatory markers have not been shown to assist in the diagnosis or treatment of pyelonephritis.¹⁴⁻¹⁸
- Blood cultures should be considered only in diagnostically ambiguous situations, when patients fail to improve

TABLE 1

Complicating Factors in Acute Pyelonephritis

Abnormal urinary tract anatomy or function; obstruction
 Chronic catheterization or recent urinary tract instrumentation
 Immunosuppression
 Increased risk of multidrug-resistant organisms (Table 2)
 Male sex*
 Older age, frailty
 Pregnancy
 Significant comorbidities (e.g., diabetes mellitus, organ transplant, sickle cell disease)

Note: These factors predispose patients to more severe illness, sepsis, and treatment failure.

*—Because of the potential for prostatic involvement and need for longer duration of antibiotic therapy, male sex is often considered a complicating factor in pyelonephritis.

Information from references 6 and 7.

within 48 to 72 hours, or when urine culture is unlikely to grow a predominant organism (e.g., indwelling catheterization, patients already taking antibiotics). Blood cultures are positive in 10% to 40% of patients with acute pyelonephritis, but the presence of bacteremia rarely affects therapy.^{8,19-22}

- Initial imaging is not recommended in uncomplicated cases of acute pyelonephritis.²³
- Diagnostic imaging to identify obstruction or structural abnormalities should be considered in the following circumstances^{23,24}:
 - Sepsis
 - Concern for urolithiasis
 - New renal insufficiency with glomerular filtration rate less than or equal to 40 mL per minute per 1.73 m²
 - Known urologic abnormalities
 - Failure to respond to appropriate therapy within 48 to 72 hours
- When diagnostic imaging is indicated, contrast-enhanced computed tomography of the abdomen and pelvis is the preferred modality.^{23,25}
- When contrast or radiation is contraindicated, such as during pregnancy, ultrasonography and magnetic resonance imaging may be used.²³

Treatment

INPATIENT VS. OUTPATIENT TREATMENT

- Outpatient management is appropriate in patients with uncomplicated pyelonephritis who are able to tolerate oral antibiotics and do not have clinical signs of sepsis. Indications for hospitalization are listed in *Table 3*.^{8,9}
- Evidence supports extended emergency department or observation unit stays as safe alternatives to immediate hospitalization for patients who warrant initial intravenous fluid resuscitation and/or are initially unable to tolerate oral agents but do not have complicating features or sepsis.^{7,9,26}
- A treatment algorithm is provided in *Figure 1*.

SUPPORTIVE CARE

- All patients should receive supportive care, as appropriate, with oral or intravenous fluid hydration, analgesics, antipyretics, and antiemetic medications.⁷
- Patients presenting with signs of sepsis should receive intravenous crystalloid fluid resuscitation (30 mL per kg) within the first hour of presentation.²⁷

ANTIMICROBIAL THERAPY

- Choice of antibiotic is informed by the clinical presentation, the patient’s individual risk factors, and local resistance patterns. Therapy should be directed by urine culture susceptibility testing when available.⁷

TABLE 2

Risk Factors for Multidrug-Resistant Organisms in Acute Pyelonephritis

- Antimicrobial use within the past 3 months (particularly fluoroquinolones and antipseudomonal penicillins)
- History of multidrug-resistant urinary isolate (e.g., extended-spectrum beta-lactamase-producing organisms)
- Hospitalization or institutionalization within the past 3 months
- Indwelling urinary catheters
- Travel outside the United States within the past 30 days
- Urologic abnormalities

Information from references 5 and 7.

TABLE 3

Indications for Hospitalization in Patients with Acute Pyelonephritis

Absolute indications

- Concurrent urinary tract obstruction
- Failure of outpatient therapy
- Oral antibiotic intolerance
- Pregnancy
- Sepsis
- Unstable coexisting medical conditions


Relative indications

- Frailty or poor social support
- High risk of infection with multidrug-resistant organism; hospital-acquired infection (Table 2)
- Severe, refractory pain
- Significant comorbidities or immunosuppression (e.g., diabetes mellitus, malignancy, organ transplant, sickle cell disease)
- Unreliable follow-up care

Information from references 8 and 9.

- Nitrofurantoin and fosfomycin (Monurol) do not attain adequate renal tissue concentration and should not be used to treat pyelonephritis.⁷
- Options for oral antibiotic regimens for outpatients are listed in *Table 4*.⁷ Fluoroquinolones and trimethoprim/sulfamethoxazole have a significant evidence base that supports their use as safe and effective first-line oral therapies, with greater than 90% clinical success rates when the causative pathogens are susceptible.⁷
- When local resistance to the chosen oral agent likely exceeds 10%, a single dose of a long-acting broad-spectrum parenteral antibiotic (e.g., ceftriaxone, ertapenem [Invanz],

FIGURE 1



*—Risk factors for infection with a multidrug-resistant organism include prior multidrug-resistant organism isolate on culture, antibiotic exposure in the past 3 months, hospitalization or institutionalization in the past 3 months, indwelling catheter or urologic abnormality, and travel outside the United States within the past 30 days.

Algorithm for treatment of acute pyelonephritis.

aminoglycosides) should also be given while awaiting susceptibility results⁷ (Table 5^{7,28}).

- Oral beta-lactams are inferior to trimethoprim/sulfamethoxazole and should not be used as first-line treatment of acute pyelonephritis.⁷
- Hospitalized patients should initially receive parenteral antibiotic therapy; empiric options are listed in Table 6.⁷⁻⁹
- Agents with activity against extended-spectrum beta-lactamase-producing organisms should be considered in patients with sepsis or risk factors for drug resistance (Table 7).^{7,9,27-29}

TREATMENT DURATION

- A systematic review of eight randomized controlled trials (N = 2,515) demonstrated equivalent clinical success rates in treating uncomplicated acute pyelonephritis with a five- to seven-day course of fluoroquinolones compared with a 14-day course.³⁰
- There is limited evidence on the effectiveness of shorter courses (less than 14 days) of trimethoprim/sulfamethoxazole. More studies are warranted before such treatment can be recommended.^{7,30}
- Acute pyelonephritis responds to appropriate therapy within 48 to 72 hours in more than 95% of cases.²⁵
- Patients not responding as expected (e.g., persistent fever, unimproved symptoms) should be further evaluated for alternative diagnoses, urinary tract obstruction, and/or antibiotic resistance with imaging, laboratory studies, blood cultures, and repeat urine culture.^{7-9,23}

Special Considerations

UROLOGIC ABNORMALITIES AND/OR OBSTRUCTION

- Urgent decompression is recommended in patients with acute pyelonephritis and urinary tract obstruction identified on imaging.^{8,9}

TABLE 4

Options for Outpatient Antibiotic Treatment in Adults with Acute Pyelonephritis

Agent and dosing	Length of treatment	Comments/pregnancy safety
Amoxicillin/clavulanate (Augmentin), 875 mg/125 mg twice daily*	10 to 14 days	May use during pregnancy; has coverage for <i>Enterococcus</i> but not useful as empiric treatment for other organisms because of resistance patterns
Cefixime (Suprax), 400 mg once daily*	10 to 14 days	May use during pregnancy, limited evidence for use
Cefpodoxime, 200 mg twice daily*	10 to 14 days	May use during pregnancy, limited evidence for use
Cephalexin (Keflex), 500 mg twice daily*	10 to 14 days	May use during pregnancy, increased resistance risk
Ciprofloxacin, 500 mg twice daily†	7 days	No known risk of teratogenicity based on human and animal data
Ciprofloxacin extended release, 1,000 mg once daily†	7 days	No known risk of teratogenicity based on human and animal data
Levofloxacin (Levaquin), 750 mg once daily†	5 days	No known risk of teratogenicity based on human and animal data
Trimethoprim/sulfamethoxazole, 160 mg/800 mg twice daily‡	14 days	Avoid use during pregnancy

*—Limited evidence or less effective; use only in combination with initial broad-spectrum parenteral agent or as guided by susceptibility testing.

†—If local resistance likely exceeds 10%, an initial single dose of a parenteral agent is recommended (Table 5).

‡—Because of increased resistance rates, an initial single dose of a parenteral agent is recommended (Table 5).

Information from reference 7.

TABLE 5

Options for Initial Parenteral Antibiotic Treatment in Combination with Oral Therapy for Acute Pyelonephritis

Agent and dosing	Comments/pregnancy safety
Ceftriaxone, 1 g one time	May use during pregnancy
Ertapenem (Invanz), 1 g one time	May use during pregnancy; effective against extended-spectrum beta-lactamase-producing organisms
Gentamicin, 5 mg per kg one time	Avoid use during pregnancy*; can be nephrotoxic
Plazomicin (Zemdri), 15 mg per kg one time	Newer agent with activity against extended-spectrum beta-lactamase-producing organisms; limited evidence; cost and availability limit use; uncertain pregnancy safety

*—Gentamicin has been studied in pregnant patients, and although its use is generally not recommended during pregnancy, the benefits may outweigh the risk of congenital malformations in certain situations, particularly in the intrapartum period.

Information from references 7 and 28.

ACUTE PYELONEPHRITIS

- Patients with structural urologic abnormalities or obstruction may benefit from longer antibiotic courses (10 to 14 days).²³
- To expedite clinical improvement, indwelling catheters that have been in place for two weeks or longer should be removed or replaced.³¹

PREGNANT PATIENTS

- Pyelonephritis affects approximately 2% of all pregnancies, with 80% to 90% of cases occurring during the second and third trimesters.^{32,33}
- Pyelonephritis is associated with significant morbidity and mortality during pregnancy, with observed rates of septicemia and respiratory failure in 17% and 7% of patients, respectively.^{32,34}
- Because of the increased risk of serious complications, pregnant patients with pyelonephritis should be admitted

to the hospital for initial parenteral antibiotic therapy and monitoring.^{33,35}

- Treatment options for pyelonephritis in pregnancy are limited because of a lack of evidence regarding antibiotic safety in utero. A Cochrane review of 10 trials (N = 1,125) found cefazolin or ceftriaxone to be effective.³²
- Pyelonephritis recurs in 6% to 8% of pregnant patients, and some experts have advocated for antibiotic suppression therapy with nitrofurantoin or cephalexin (Keflex)

TABLE 6

Empiric Parenteral Antibiotic Treatment Options in Adults with Mild to Moderate Acute Pyelonephritis

Agent and dosing	Comments/pregnancy safety
Cefepime, 1 to 2 g once daily	May use during pregnancy; consider dosage of 2 g every 8 hours when <i>Pseudomonas aeruginosa</i> is suspected
Ceftriaxone, 1 g once daily	May use during pregnancy
Ciprofloxacin, 400 mg every 12 hours	No known risk of teratogenicity based on human and animal data; good oral bioavailability; consider transition to oral dosing when tolerated
Gentamicin, 5 mg per kg once daily	Avoid use during pregnancy*; can be given as parenteral dose for 24 to 48 hours to augment oral regimen; can be nephrotoxic
Levofloxacin (Levaquin), 750 mg once daily	No known risk of teratogenicity based on human and animal data; good oral bioavailability; consider transition to oral dosing when tolerated
Piperacillin/tazobactam (Zosyn), 3.375 to 4.5 g every 6 hours	May use during pregnancy; use 4.5-g dosage when <i>P. aeruginosa</i> is suspected

*—Gentamicin has been studied in pregnant patients, and although its use is generally not recommended during pregnancy, the benefits may outweigh the risk of congenital malformations in certain situations, particularly in the intrapartum period.

Information from references 7-9.

TABLE 7

Empiric Parenteral Antibiotic Treatment Options in Adults with Sepsis or Increased Risk of Infection with Extended-Spectrum Beta-Lactamase–Producing Organisms

Agent and dosing	Comments/pregnancy safety
Ceftazidime/avibactam (Avycaz), 2.5 g every 8 hours	Newer agent with limited evidence; cost and availability limit usage; uncertain pregnancy safety
Ceftolozane/tazobactam (Zerbaxa), 1.5 g every 8 hours	Newer agent with limited evidence; cost and availability limit usage; uncertain pregnancy safety
Ertapenem (Invanz), 1 g once daily	May use during pregnancy; useful dosing for outpatients; increased resistance among some extended-spectrum beta-lactamase–producing organisms, use when susceptible
Imipenem/cilastatin (Primaxin), 500 mg every 6 hours	Uncertain pregnancy safety
Meropenem (Merrem IV), 1 g every 8 hours	Uncertain pregnancy safety
Meropenem/vaborbactam (Vabomere), 2 g/2 g every 8 hours	Newer agent with limited evidence; cost and availability limit usage; uncertain pregnancy safety
Piperacillin/tazobactam (Zosyn), 3.375 to 4.5 g every 6 hours	May use during pregnancy; increased resistance among some extended-spectrum beta-lactamase–producing organisms, resistance can develop during treatment; use 4.5-g dosage when <i>Pseudomonas aeruginosa</i> is suspected
Plazomicin (Zemdri), 15 mg per kg once daily	Newer agent with limited evidence; cost and availability limit usage; uncertain pregnancy safety

Information from references 7, 9, and 27-29.

to reduce the risk of recurrence. However, data are insufficient to support this practice.³⁶

MEN

- Data are lacking on the appropriate treatment length and regimen for men with acute pyelonephritis.³⁰
- In the male subgroup of one randomized controlled trial, a seven-day course of ciprofloxacin was inferior to a 14-day course with respect to short-term cure rates, with no differences in long-term outcomes.³⁷

This article updates previous articles on this topic by Colgan, et al.,⁸ and by Ramakrishnan and Scheid.⁶

Data Sources: A PubMed search was completed using Clinical Queries and medical subject headings with key terms pyelonephritis epidemiology; pyelonephritis microbiology; pyelonephritis risk factors; pyelonephritis diagnosis; pyelonephritis treatment; pyelonephritis length of treatment, hospitalization; and pyelonephritis, outpatient management of pyelonephritis. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were Essential Evidence Plus, the Cochrane database, UpToDate, clinical guidelines and practice bulletins from the American College of Obstetricians and Gynecologists and the Infectious Diseases Society of America, and evidence reports from the Agency for Healthcare Research and Quality. Search dates: July 3 and 27, 2019; August 6, 2019; and May 4, 2020.

The authors thank Anne Mounsey, MD, for mentorship, guidance, and review of the manuscript.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Air Force, the U.S. Navy, the Department of Defense, or the U.S. government.

The Authors

JOEL HERNESS, MD, is a faculty member of the Family Medicine Residency Program at Mike O'Callaghan Military Medical Center, Nellis Air Force Base, Nev., and an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md.

AMELIA BUTTOLPH, MD, is the associate program director of the Camp Lejeune (N.C.) Family Medicine Residency Program and an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences.

NOA C. HAMMER, MD, MPH, is the program director of the Naval Hospital Camp Pendleton (Calif.) Family Medicine Residency Program and an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences.

Address correspondence to Joel Herness, MD, Mike O'Callaghan Military Medical Center, Family Medicine Residency, 4700 Las Vegas Blvd. N., Nellis AFB, NV 89191 (email: joelherness@gmail.com). Reprints are not available from the authors.

References

1. Nicolle LE. Epidemiology of urinary tract infection. *Clin Microbiol Newsl.* 2002;24(18):135-140.
2. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. *Ann Epidemiol.* 2003;13(2):144-150.
3. Czaja CA, Scholes D, Hooton TM, et al. Population-based epidemiologic analysis of acute pyelonephritis. *Clin Infect Dis.* 2007;45(3):273-280.
4. Scholes D, Hooton TM, Roberts PL, et al. Risk factors associated with acute pyelonephritis in healthy women. *Ann Intern Med.* 2005;142(1):20-27.
5. Talan DA, Takhar SS, Krishnadasan A, et al.; EMERGENCY ID Net Study Group. Fluoroquinolone-resistant and extended-spectrum β -lactamase-producing *Escherichia coli* infections in patients with pyelonephritis, United States. *Emerg Infect Dis.* 2016;22(9):1594-1603.
6. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults [published correction appears in *Am Fam Physician.* 2005;72(11):2182]. *Am Fam Physician.* 2005;71(5):933-942. Accessed March 27, 2020. <https://www.aafp.org/afp/2005/0301/p933.html>
7. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis.* 2011;52(5):e103-e120.
8. Colgan R, Williams M, Johnson JR. Diagnosis and treatment of acute pyelonephritis in women. *Am Fam Physician.* 2011;84(5):519-526. Accessed March 27, 2020. <https://www.aafp.org/afp/2011/0901/p519.html>
9. Johnson JR, Russo TA. Acute pyelonephritis in adults. *N Engl J Med.* 2018;378(12):1162.
10. Lifshitz E, Kramer L. Outpatient urine culture: does collection technique matter? *Arch Intern Med.* 2000;160(16):2537-2540.
11. Bradbury SM. Collection of urine specimens in general practice: to clean or not to clean? *J R Coll Gen Pract.* 1988;38(313):363-365.
12. Immergut MA, Gilbert EC, Frensilij FJ, et al. The myth of the clean catch urine specimen. *Urology.* 1981;17(4):339-340.
13. Bray PA, Corry MF. Mid-stream urine collection: is preparatory cleansing essential? *N Z Nurs J.* 1979;72(3):13-14.
14. Kang C, Kim K, Lee SH, et al. A risk stratification model of acute pyelonephritis to indicate hospital admission from the ED. *Am J Emerg Med.* 2013;31(7):1067-1072.
15. Stalenhoef JE, van Nieuwkoop C, Wilson DC, et al. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection. *BMC Infect Dis.* 2019;19(1):161.
16. Claessens YE, Schmidt J, Batard E, et al. Can C-reactive protein, procalcitonin and mid-regional pro-atrial natriuretic peptide measurements guide choice of in-patient or out-patient care in acute pyelonephritis? Biomarkers In Sepsis (BIS) multicentre study. *Clin Microbiol Infect.* 2010;16(6):753-760.
17. Park JH, Wee JH, Choi SP, et al. Serum procalcitonin level for the prediction of severity in women with acute pyelonephritis in the ED: value of procalcitonin in acute pyelonephritis. *Am J Emerg Med.* 2013;31(7):1092-1097.
18. Seo DY, Jo S, Lee JB, et al. Diagnostic performance of initial serum lactate for predicting bacteremia in female patients with acute pyelonephritis. *Am J Emerg Med.* 2016;34(8):1359-1363.
19. Karakonstantis S, Kalemaki D. Blood culture useful only in selected patients with urinary tract infections—a literature review. *Infect Dis (Lond).* 2018;50(8):584-592.
20. Chen Y, Nitzan O, Saliba W, et al. Are blood cultures necessary in the management of women with complicated pyelonephritis? *J Infect.* 2006;53(4):235-240.

ACUTE PYELONEPHRITIS

21. Gomi H, Goto Y, Laopaiboon M, et al. Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes. *Cochrane Database Syst Rev*. 2015;(2):CD009216.
22. Kim Y, Seo MR, Kim SJ, et al. Usefulness of blood cultures and radiologic imaging studies in the management of patients with community-acquired acute pyelonephritis. *Infect Chemother*. 2017;49(1):22-30.
23. Nikolaidis P, Dogra VS, Goldfarb S, et al.; Expert Panel on Urologic Imaging. ACR Appropriateness Criteria® acute pyelonephritis. *J Am Coll Radiol*. 2018;15(11S):S232-S239.
24. van Nieuwkoop C, Hoppe BP, Bonten TN, et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. *Clin Infect Dis*. 2010;51(11):1266-1272.
25. Soulen MC, Fishman EK, Goldman SM, et al. Bacterial renal infection: role of CT. *Radiology*. 1989;171(3):703-707.
26. Ward G, Jordan RC, Severance HW. Treatment of pyelonephritis in an observation unit. *Ann Emerg Med*. 1991;20(3):258-261.
27. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. *JAMA*. 2018;319(8):788-799.
28. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al.; EPIC Study Group. Once-daily plazomicin for complicated urinary tract infections. *N Engl J Med*. 2019;380(8):729-740.
29. Golan Y. Empiric therapy for hospital-acquired, gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. *BMC Infect Dis*. 2015;15:313.
30. Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother*. 2013;68(10):2183-2191.
31. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(5):625-663.
32. Vazquez JC, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. *Cochrane Database Syst Rev*. 2011;(1):CD002256.
33. Matuszkiewicz-Rowińska J, Matyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. *Arch Med Sci*. 2015;11(1):67-77.
34. Hill JB, Sheffield JS, McIntire DD, et al. Acute pyelonephritis in pregnancy. *Obstet Gynecol*. 2005;105(1):18-23.
35. Brooks AM, Garite TJ. Clinical trial of the outpatient management of pyelonephritis in pregnancy. *Infect Dis Obstet Gynecol*. 1995;3(2):50-55.
36. Schneeberger C, Geerlings SE, Middleton P, et al. Interventions for preventing recurrent urinary tract infection during pregnancy. *Cochrane Database Syst Rev*. 2015;(7):CD009279.
37. van Nieuwkoop C, van der Starre WE, Stalenhoef JE, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. *BMC Med*. 2017;15(1):70.

eTABLE A

Causative Organisms in Acute Pyelonephritis (United States)

Uropathogen	Total (n = 521)	Uncomplicated (n = 286)	Complicated* (n = 235)
<i>Escherichia coli</i>	86.9%	95.1%	77.0%
<i>Klebsiella pneumoniae</i>	4.8%	1.4%	8.9%
<i>Enterococcus</i>	2.3%	0%	5.1%
<i>Pseudomonas</i>	1.3%	0%	3.0%
<i>Enterobacter</i>	1.0%	0.3%	1.7%
<i>Proteus</i>	0.8%	1.0%	0.4%
<i>Staphylococcus aureus</i>	0.8%	0%	1.7%
Group B streptococcus	0.4%	0.3%	0.4%
<i>Staphylococcus saprophyticus</i>	0.4%	0.7%	0%
Other	1.0%	0.7%	1.3%

*—See Table 1.

Adapted from Talan DA, Takhar SS, Krishnadasan A, et al.; EMERGENCY ID Net Study Group. Fluoroquinolone-resistant and extended-spectrum β -lactamase-producing *Escherichia coli* infections in patients with pyelonephritis, United States. *Emerg Infect Dis*. 2016;22(9):1598.